|
First-in-human study of TQB3617, a BET inhibitor in patients with relapsed/refractory hematologic malignancies. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Chia Tai Tianqing Pharmaceutical Group |
|
|
Employment - Chia Tai Tianqing Pharmaceutical Group |
|
|
Employment - Chia Tai Tianqing Pharmaceutical Group |
|
|
No Relationships to Disclose |
|
|
Employment - Chia Tai Tianqing Pharmaceutical Group |